(Revised on September 18, 2024)

1.Requirements for the submission of manuscripts.

The first and corresponding authors have to be members of Japanese Society of Gout and Uric & Nucleic Acids, except for authors of review papers invited by the editorial committee.

2.Acceptance or rejection of the paper.

The editorial committee will decide whether to accept or reject manuscripts after peer review.

3.Publication.

Gout and Uric & Nucleic Acids is published twice a year in principle. However, manuscripts may be submitted at any time.

4.Types of papers

We accept original articles, review papers, case reports, brief reports, and communications and other papers on gout and uric/nucleic acid metabolism. However, submission to preprints is permitted. Papers that have already been published in/submitted to other journals cannot be accepted except for those published at pre-print archives. Presentations held at the annual meeting of Japanese Society of Gout and Uric & Nucleic Acids will be actively published, so the authors are encouraged to submit their papers within three months of the presentation. We also accept general submissions.

Original Articles

Original articles must be written in the following order: the title, the names of authors, affiliations, key words, Abstract (the word limit is 250 words), Introduction, Methods (or Case presentation), Results, Discussion, Acknowledgement, COI, References.

Format:

1. Manuscripts must be written on A4 paper with up to 4,000 words. The numbers of words from the Abstract to COI, including tables, and figures (each Table or Figure equivalent to 160 words), are counted. Characters/words in References are not included.
2. The cover of the manuscript should contain the title, the full names of the authors and the organizations. You may add your maiden name. It should also contain up to five key words, and the contact information of the corresponding author, including a telephone number, fax number, and e-mail address.
3. Supplemental data must be in PDF format only. They will be only published as an electronic appendix.
4. For substances that are not publicly available, the authors should clearly state their structural formula.

Review Articles

Review articles are published based on requests by the editorial committee. However, members of the society are allowed to submit manuscripts written on subjects of their interest, which will undergo review. Review articles should be written in the same format as that of original articles, with up to 4,800 words.

Case Reports / Brief Reports

Case reports / brief reports should be written according to the guidelines for original articles. These reports should be written in the same format as that of original articles. The numbers of words for case reports must be 2,000 or less. The numbers of words for brief reports must be 1,200 or less.

Communication

Submissions are welcome when they are considered useful in basic research and clinical practice mainly in the fields of medical professionals. The number of characters must be up to 1,500 words. The word count is calculated as 100 characters per figure, table, or photo.

5. Instruction of submission

Manuscripts should be sent to the following e-mail address together with abstracts, tables, figures, and pictures. “The name of the first author” should be used as the title of the body text file,
and table and figure files should be titled “Figure 1”, “Table 2”, etc. In principle use MS Word for the body text and tables, and PDF or TIF format should be used for figures. If authors wish to submit manuscripts using other file formats (RTF, JPG, etc.), contact the editorial office. Please include PDF files of the complete manuscript to check for garbled characters and color aberration.

*Submit manuscripts to/contact the following to ask questions about editing:

Editorial Office: Gout and Uric & Nucleic Acids
3rd Floor, Shiba Yagyu Building, 2-12-3 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan
Editorial Office of the Japanese Society of Gout and Uric & Nucleic Acids
E-Mail: htakeuti@tukaku.jp

*If you wish to become a member of the Japanese Society of Gout and Uric & Nucleic Acids, please visit our website (http://www.tukaku.jp). The bank transfer form to pay annual membership fees will be sent to you following the acceptance of the application.

6. Manuscript preparation

a.Figures must be clear enough to be printed as they are. Each figure/table must be accompanied by a title and figure legend.

b.The References should be formatted as follows:

• a)Superscript numbers corresponding to the numbers in the Reference should be written in the upper-right of each citation with a bracket in the order of citation.
• b)Format
  [Journal]: Name of the author, title of the paper, name of the journal, volume: the first- last pages, year of publication
  [Books]: Name of the author, title of the paper, name of the book, name of the editor, publisher, the first – last pages, year of publication
• c)Names of up to three authors (in the order of the last and first names) should be written accompanied with “et al.” (if the number of authors is more than three).
• d)Abbreviated names of journals should comply with Index Medicus.
  Example:
  1)Walker BR, Hoppe RC, Alexander F, et al: Effect of triamteren on the renal clearance of calcium, magnesium, phosphate, and uric acid in man. Clin Pharmacol Ther 13: 245-250, 1972.
  2)Wyngaarden JB, Kelley WN: Production of Uric Acid in Primary Gout. Gout and Hyperuricemia, Grune & Stratton, pp133-148, 1976.
  3)Seegmiller JE: Diseases of purine and pyrimidine metabolism. Duncan’s Diseases of Metabolism, Bondy PK, Posenberg LE (eds), 7th ed. W.B. Saunders Company, Philadelphia, pp 655-656, 1974.

c.Although the Editorial Board will make every effort to include tables and figures in specified areas, authors’ requests may not be met if there are a large number of tables and figures. (Please limit the number of tables and figures).

d.Please note that styles may be modified so that we use our standard styles to format the journal.
Example:
Units for metrological standards should be written using the following print letters without the ellipsis.
μL mL dL: μg mg g kg: nm mm cm: sec min hr: nM μM mM M: nmol μmol mmol mol

e.The authors are required to comply with the following ethics guidelines: The Declaration of Helsinki (adopted in 1964 and revised in the World Medical Association General Assembly at Tokyo [1975], Venice [1983], Hongkong [1989], Somerset West [1996], Edinburgh [2000], Seoul [2008], and Fortaleza [2013]; Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare, Ministry of Economy, Trade and Industry : published on March 23, 2021, partially revised on March 27, 2023); Ethical Guidelines for Human Genome and Genetic Analysis Research (Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry: published on February 8, 2013, partially revised February 28, 2017); “The Ethical Guidelines for Epidemiological Research” for Survey Research (completely revised on June 17, 2002, and December 28, 2004, partially revised on June 29, 2005, completely revised on August 16, 2007, partially revised on December 1, 2008); “The Standard for Care and Management of Laboratory Animals and Relief of Pain.” for Research involving Animals (published on April 28, 2006, and finally revised in 2013), and stipulate other governing laws and regulations on an as-required basis

f. As for the approval of the ethics committee, clinical trials need to undergo review conducted by the facilities or relevant public organizations. Please describe whether or not clinical trials have been approved in the body text.

7. Proofreading

When authors proofread their accepted manuscripts, they must not add or delete sentences.
The editorial department also proofreads English papers. However, if authors who have proofread their English papers do not request English proofreading, please inform the editorial department following the acceptance of the paper. Authors are only required to proofread the authors’ manuscript.

8. Publication fee:

No publication fee is required.

9. Copyright

Copyright of materials published in the journal is owned by the Japanese Society of Gout and Uric & Nucleic Acids. Papers published in the journal will be available on the Internet (website of the academic society). When using a part of materials, such as tables and figures, published in the journal, please submit “a request for permission for reprinting/using materials” to obtain the approval of the Editor in Chief. When quoting figures and tables from other journals, please obtain permission from that journal if necessary, and clearly state this in the figures and tables.
When the objectives of reprints to other journals or electronic citations are considered to be other than academic purposes, permission fees will be required and paid to the Japanese Society of Gout and Uric & Nucleic Acids.

10. Conflicts of Interest disclosure by authors who submit papers

The disclosure of Conflicts of Interest (COI) by authors should be written below the body text and Acknowledgement and above References. Authors should disclose the declaration of COI when they submit papers. Please download the prescribed form from the following website:
(youshiki2.doc (live.com))
Methods for COI disclosure:

1. When there is no declaration of COI to be disclosed:
   Example: Disclosure of the authors’ COI (conflicts of interest): There is no declaration of COI regarding this paper.
2. When there are declarations of COI to be disclosed:
   Disclosure of the declaration of COI (conflicts of interest): Authors should write the names of companies, institutions, and organizations that have COI with each author regarding rewards, profits from stocks, patent royalties, fees for lectures, manuscript fees, research grants/subsidies, donations, lectures supported by donations, travel expenses/gifts (The standard amount is from youshiki2.doc (live.com) ).
   Example:
   Authors’ COI (conflicts of interest) Disclosure: Tanaka Ichiro; lecture fees (○○ Pharmaceutical,
   ○○ Pharmaceutical), donations (○○ Pharmaceutical, ○○ Pharmaceutical), Tanaka Jiro; lecture fees (○○ Pharmaceutical), research grants/subsidies(○○ Pharmaceutical), donations (△△ Pharmaceutical, ○○ Pharmaceutical), Tanaka Saburo; lecture fees (○○ Pharmaceutical, ○○ Pharmaceutical), lectures supported by donations (○○ Pharmaceutical), travel expenses/gifts (○○ Pharmaceutical)